Positron emission tomography for the evaluation and treatment of cardiomyopathy
Document Type
Journal Article
Publication Date
1-1-2011
Journal
Annals of the New York Academy of Sciences
Volume
1228
Issue
1
DOI
10.1111/j.1749-6632.2011.06017.x
Keywords
Cardiomyopathy; Congestive heart failure; Molecular imaging; Positron emission tomography; Stem cells
Abstract
Congestive heart failure accounts for tremendous morbidity and mortality worldwide. There are numerous causes of cardiomyopathy, the most common of which is coronary artery disease. Positron emission tomography (PET) has an established and expanding role in the evaluation of patients with cardiomyopathy. The specific application of PET to hypertrophic cardiomyopathy, cardiac sarcoidosis, and diabetic cardiomyopathy has been studied extensively and promises to be a useful tool for managing these patients. Furthermore, evaluating the efficacy of standard treatments for congestive heart failure is important as health care costs continue to rise. Recently, there have been significant developments in the field of cardiovascular stem cell research. Familiarity with the mechanisms by which stem cells benefit patients with cardiovascular disease is the key to understanding these advances. Molecular imaging techniques including PET/CT imaging play an important role in monitoring stem cell therapy in both animals and humans. These noninvasive imaging techniques will be highlighted in this paper. © 2011 New York Academy of Sciences..
APA Citation
Shah, P., Choi, B., & Mazhari, R. (2011). Positron emission tomography for the evaluation and treatment of cardiomyopathy. Annals of the New York Academy of Sciences, 1228 (1). http://dx.doi.org/10.1111/j.1749-6632.2011.06017.x